Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
ORGANIZATION
Plaintiffs of HPV Vaccine Suits Urge MHLW Not to Reinstate Recommendation
Plaintiffs of lawsuits over post-HPV-vaccination symptoms submitted a petition to the health ministry on September 3, opposing the reinstatement of what is called an “active recommendation” for HPV jabs. The move comes in response to Health Minister Norihisa Tamura’s remarks…
To read the full story
Related Article
- MSD Says to Ensure HPV Vaccine Supply in Japan, 4 Million-Plus Syringes for FY2022
March 30, 2022
- MHLW Panel OKs Mix-and-Match HPV Vaccines in “Catch-Up” Program
January 31, 2022
- Japan Panel OKs HPV “Catch-Up” Shots for Females Born in FY1997-FY2005
December 24, 2021
- MSD Japan Hails Resumption of HPV Vaccine Recommendation
November 29, 2021
- Japan to Reinstate Recommendation for HPV Vaccination in April
November 29, 2021
- Japan Panel Agrees to Give Free “Catch-Up” HPV Shots
November 16, 2021
- Plaintiffs, Lawyers Re-Stress Opposition to HPV Vaccine Recommendation
November 15, 2021
- Japan to Reinstate HPV Vaccine Recommendation after 8 Years in Limbo
November 15, 2021
- MHLW Health Service Chief Wants Prompt Debate on HPV Recommendation
October 20, 2021
- Plaintiffs, Lawyers Renew Opposition to Restart of HPV Vaccine Recommendation
October 13, 2021
- LDP League Hails Start of Panel Discussions on HPV Vaccine Recommendation
October 13, 2021
- No Factor to Impede Reinstatement of HPV Vaccine Recommendation: Panels
October 4, 2021
- MHLW Panel to Discuss HPV Vaccine Recommendation on Oct. 1
September 29, 2021
- Japan to Start Discussions in October on Reinstating HPV Vaccine Recommendation
September 21, 2021
- MSD Urges Govt to Start HPV Vaccine Discussions as Soon as Possible
September 2, 2021
- Council to Discuss Resuming Active Recommendation of HPV Vaccines: Health Minister
September 1, 2021
- Govt Recognizes Need to Resume HPV Vaccine Discussion: Health Minister
August 31, 2021
- Govt Not Planning to Resume Active HPV Vaccine Recommendation before October: Minister
August 30, 2021
- Reinstate Active HPV Vaccine Promotion before October: LDP League
August 27, 2021
- Plaintiffs of HPV Vaccine Suits Urge LDP Group to Hear Stories of Sufferers
April 16, 2021
- LDP League Submits Request to Reinstate HPV Vaccine Promotion
March 30, 2021
- LDP Group to Submit Request for HPV Vaccine Promotion Resumption
March 26, 2021
- Reinstate “Active Recommendation” for HPV Vaccines: LDP Lawmakers’ League
July 22, 2020
ORGANIZATION
- Generic Use Rate Reaches Record 81.7% in April-June: JGA
September 29, 2023
- Assess Evaluation Methods for Innovative Medical Products: Science Council
September 28, 2023
- Ex-MHLW CMO Calls for Reasonable Pricing of Alzheimer’s Drugs
September 27, 2023
- Shipments Restricted or Halted for 22.9% of Products in August: FPMAJ
September 25, 2023
- JPMA Embarking on Creation of One-Stop Platform for Rare Disease Trial Info
September 19, 2023
A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…
The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
IntroductionCommercial transformation is a top priority for pharma leaders in Japan and rightfully so. In a market with low single…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…